Precigen, Inc. (PGEN)
NASDAQ: PGEN · IEX Real-Time Price · USD
1.590
-0.070 (-4.22%)
At close: Jul 19, 2024, 4:00 PM
1.580
-0.010 (-0.63%)
Pre-market: Jul 20, 2024, 9:29 AM EDT
Precigen Revenue
Precigen had revenue of $5.44M in the twelve months ending March 31, 2024. Revenue in the quarter ending March 31, 2024 was $1.07M. In the year 2023, Precigen had annual revenue of $6.23M.
Revenue (ttm)
$5.44M
Revenue Growth
-76.60%
P/S Ratio
73.79
Revenue / Employee
$26,926
Employees
202
Market Cap
401.35M USD
Revenue Chart
Revenue History
Fiscal Year End | Revenue | Change | Growth |
---|---|---|---|
Dec 31, 2023 | 6.23M | -20.68M | -76.87% |
Dec 31, 2022 | 26.91M | 12.64M | 88.61% |
Dec 31, 2021 | 14.27M | -17.73M | -55.40% |
Dec 31, 2020 | 31.99M | -58.73M | -64.74% |
Dec 31, 2019 | 90.72M | -60.46M | -39.99% |
Dec 31, 2018 | 151.18M | -68.29M | -31.11% |
Dec 31, 2017 | 219.46M | 28.54M | 14.95% |
Dec 31, 2016 | 190.93M | 17.32M | 9.98% |
Dec 31, 2015 | 173.61M | 101.68M | 141.35% |
Dec 31, 2014 | 71.93M | 48.17M | 202.74% |
Dec 31, 2013 | 23.76M | 9.99M | 72.50% |
Dec 31, 2012 | 13.77M | 5.76M | 71.90% |
Dec 31, 2011 | 8.01M | - | - |
Dec 31, 2010 | 0 | - | - |
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
Organogenesis Holdings | 435.47M |
Sonida Senior Living | 260.69M |
Revance Therapeutics | 236.65M |
Esperion Therapeutics | 229.74M |
Cerus | 191.72M |
Anika Therapeutics | 169.26M |
AxoGen | 163.73M |
Lyell Immunopharma | 68.00K |
PGEN News
- 6 weeks ago - Precigen Announces Groundbreaking Pivotal Study Data for PRGN-2012 in Patients with Recurrent Respiratory Papillomatosis in Which More than Half of Patients Achieved Complete Response - PRNewsWire
- 2 months ago - Precigen to Host a Webcast on June 3rd to Detail Pivotal Study Results of PRGN-2012 in Recurrent Respiratory Papillomatosis Presented at the 2024 ASCO Annual Meeting - PRNewsWire
- 2 months ago - Precigen Reports First Quarter 2024 Financial Results and Business Updates - PRNewsWire
- 2 months ago - Precigen to Announce First Quarter 2024 Financial Results on May 14th and Host a Conference Call on June 3rd following the Late-breaking Oral Presentation for PRGN-2012 at the 2024 ASCO Annual Meeting - PRNewsWire
- 3 months ago - Precigen to Present Late-breaking Abstract for Pivotal Phase 2 Study Data for PRGN-2012 AdenoVerse Immunotherapy for the Treatment of Patients with Recurrent Respiratory Papillomatosis at the 2024 ASCO Annual Meeting - PRNewsWire
- 3 months ago - Actym Therapeutics Appoints Thomas Smart as CEO - PRNewsWire
- 4 months ago - Precigen and Recurrent Respiratory Papillomatosis Foundation to Hold Inaugural International RRP Awareness Day on June 11th - PRNewsWire
- 4 months ago - Precigen Reports Full Year 2023 Financial Results and Business Updates - PRNewsWire